Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MONIKA FISCHER

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1023264900
CMS profile
318170
Location
INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$64,765.83

70 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $20,769.96 17
Ferring Pharmaceuticals Inc. $10,255.93 4
Eli Lilly and Company $8,800.00 1
Lilly USA, LLC $8,575.74 14
ABBVIE INC. $7,642.05 24
Janssen Scientific Affairs, LLC $5,340.94 4
PFIZER INC. $3,000.00 1
Janssen Biotech, Inc. $189.48 2
Medtronic, Inc. $129.31 1
Celgene Corporation $62.42 2

Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MONIKA FISCHER

NPI 1023264900 · CMS profile ID 318170

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023264900?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MONIKA FISCHER, NPI 1023264900, CMS profile ID 318170. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023264900?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MONIKA FISCHER, NPI 1023264900, CMS profile ID 318170. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023264900?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MONIKA FISCHER, NPI 1023264900, CMS profile ID 318170, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1023264900?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

70 matching records · $64,765.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 70 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–70 of 70.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $160.7508/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918186623 CMS
Lilly USA, LLC $337.6608/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918208303 CMS
Lilly USA, LLC $160.6408/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918270469 CMS
ABBVIE INC. $64.6207/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890962757 CMS
ABBVIE INC. $16.3506/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890962755 CMS
Ferring Pharmaceuticals Inc. $4,650.0006/14/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 875348813 CMS
Ferring Pharmaceuticals Inc. $18.3206/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 875348809 CMS
Ferring Pharmaceuticals Inc. $25.6106/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 875348811 CMS
Janssen Biotech, Inc. $50.3805/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885898207 CMS
E.R. Squibb & Sons, L.L.C. $4,290.0004/27/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932552849 CMS
Celgene Corporation $47.4004/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932552855 CMS
ABBVIE INC. $11.5504/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890962753 CMS
ABBVIE INC. $58.2103/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890962749 CMS
ABBVIE INC. $14.7303/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890962751 CMS
ABBVIE INC. $23.1503/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890962747 CMS
Eli Lilly and Company $8,800.0003/10/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918252537 CMS
Medtronic, Inc. $129.3103/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930272203 CMS
ABBVIE INC. $5.4701/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890962745 CMS
ABBVIE INC. $100.6201/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890962743 CMS
PFIZER INC. $3,000.0001/14/2022 Honoraria No dispute reported Delay: No
Change: CHANGED
06/30/2026 949353387 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $25,999.42 59
PY2020 $5,242.65 8
PY2021 $3,154.29 17
PY2022 $64,765.83 70
PY2023 $43,116.76 69
PY2024 $41,737.13 87
PY2025 $74,015.13 86

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $592,426.82 86
PY2024 Principal investigator $390,227.66 45
PY2023 Principal investigator $267,004.34 29
PY2022 Principal investigator $556,853.49 17
PY2021 Principal investigator $307,777.81 13
PY2020 Recipient $11.46 1
PY2020 Principal investigator $148,338.60 10
PY2019 Recipient $960.00 1
PY2019 Principal investigator $291,799.41 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

86 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 F. Hoffmann-La Roche AG $1,699.00 12/19/2025 Non-covered Recipient Entity
Indiana University
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211614525
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,910.66 12/19/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease Dispute reported 06/30/2026 1223266963
Principal investigator 1 F. Hoffmann-La Roche AG $13,156.00 12/11/2025 Non-covered Recipient Entity
Indiana University
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211614522
Principal investigator 1 F. Hoffmann-La Roche AG $3,000.00 12/11/2025 Non-covered Recipient Entity
Indiana University
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211614529
Principal investigator 1 F. Hoffmann-La Roche AG $15,200.00 12/11/2025 Non-covered Recipient Entity
Indiana University
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211614536
Principal investigator 1 F. Hoffmann-La Roche AG $10,462.00 12/04/2025 Non-covered Recipient Entity
Indiana University
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211614533
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,000.00 12/04/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE Dispute reported 06/30/2026 1223266949
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 12/04/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE Dispute reported 06/30/2026 1223266951
Principal investigator 1 Genentech, Inc. $3,176.00 11/25/2025 Non-covered Recipient Entity
Indiana University
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211614583
Principal investigator 1 Genentech, Inc. $1,030.00 11/25/2025 Non-covered Recipient Entity
Indiana University
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211614587
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,780.94 11/25/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease Dispute reported 06/30/2026 1223266947
Principal investigator 1 Genentech, Inc. $6,689.00 11/14/2025 Non-covered Recipient Entity
Indiana University
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211614575
Principal investigator 1 Genentech, Inc. $3,456.00 11/07/2025 Non-covered Recipient Entity
Indiana University
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211614579
Principal investigator 1 Genentech, Inc. $2,980.00 10/29/2025 Non-covered Recipient Entity
Indiana University
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211614571
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,150.58 10/29/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease Dispute reported 06/30/2026 1223266935
Principal investigator 1 ABBVIE INC. $1,000.00 10/15/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202516983
Principal investigator 1 ABBVIE INC. $5,837.12 10/09/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202515763
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $632.00 10/08/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL Dispute reported 06/30/2026 1223266927
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $632.00 10/08/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL Dispute reported 06/30/2026 1223266929
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,329.27 10/03/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease Dispute reported 06/30/2026 1223266925
Principal investigator 1 Eli Lilly and Company $8,200.00 10/02/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
MIRIKIZUMAB LY3074828 PRO UC CD - OMVOH - ULCERATIVE COLITIS No dispute reported 06/30/2026 1187881582
Principal investigator 1 F. Hoffmann-La Roche AG $104.00 09/23/2025 Non-covered Recipient Entity
Indiana University
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211614498
Principal investigator 1 F. Hoffmann-La Roche AG $450.00 09/23/2025 Non-covered Recipient Entity
Indiana University
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211614510
Principal investigator 1 F. Hoffmann-La Roche AG $3,252.00 09/23/2025 Non-covered Recipient Entity
Indiana University
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211614518
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,451.67 09/23/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease Dispute reported 06/30/2026 1223266915
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,669.00 09/23/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease Dispute reported 06/30/2026 1223266917
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,200.00 09/23/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease Dispute reported 06/30/2026 1223266919
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,836.00 09/23/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease Dispute reported 06/30/2026 1223266921
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 09/23/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease Dispute reported 06/30/2026 1223266923
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,044.09 09/18/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease Dispute reported 06/30/2026 1223266911
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $632.00 09/15/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL Dispute reported 06/30/2026 1223266905
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,868.98 09/12/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease Dispute reported 06/30/2026 1223266903
Principal investigator 1 ABBVIE INC. $37,523.76 09/04/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202509766
Principal investigator 1 ABBVIE INC. $13,042.40 09/04/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202509768
Principal investigator 1 ABBVIE INC. $5,500.00 09/04/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202509770
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,451.67 09/04/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease Dispute reported 06/30/2026 1223266901
Principal investigator 1 ABBVIE INC. $24,752.00 09/03/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202508170
Principal investigator 1 F. Hoffmann-La Roche AG $3,000.00 08/07/2025 Non-covered Recipient Entity
Indiana University
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211614494
Principal investigator 1 F. Hoffmann-La Roche AG $9,656.00 08/07/2025 Non-covered Recipient Entity
Indiana University
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211614502
Principal investigator 1 F. Hoffmann-La Roche AG $3,500.00 08/07/2025 Non-covered Recipient Entity
Indiana University
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211614506
Principal investigator 1 F. Hoffmann-La Roche AG $15,200.00 08/07/2025 Non-covered Recipient Entity
Indiana University
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211614514
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,451.67 08/07/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease Dispute reported 06/30/2026 1223266891
Principal investigator 1 ABBVIE INC. $11,772.16 08/06/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202503033
Principal investigator 1 ABBVIE INC. $6,089.39 08/06/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202503035
Principal investigator 1 ABBVIE INC. $15,917.76 07/31/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202500674
Principal investigator 1 ABBVIE INC. $22,876.00 07/31/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202500676
Principal investigator 1 Eli Lilly and Company $1,014.88 07/28/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187882056
Principal investigator 1 Eli Lilly and Company $942.88 07/28/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187882846
Principal investigator 1 F. Hoffmann-La Roche AG $1,300.00 07/22/2025 Non-covered Recipient Entity
Indiana University
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211614489
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,913.07 07/22/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease Dispute reported 06/30/2026 1223266881
Principal investigator 1 ABBVIE INC. $2,860.08 07/02/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202495599
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,639.00 06/25/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET Dispute reported 06/30/2026 1223266879
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,400.00 06/18/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL Dispute reported 06/30/2026 1223266875
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $110.00 06/18/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL Dispute reported 06/30/2026 1223266877
Principal investigator 1 ABBVIE INC. $2,300.00 06/09/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202490651
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $632.00 06/06/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL Dispute reported 06/30/2026 1223266871
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $632.00 06/06/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL Dispute reported 06/30/2026 1223266873
Principal investigator 1 ABBVIE INC. $16,378.48 06/03/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202488335
Principal investigator 1 Eli Lilly and Company $7,108.00 05/27/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 No dispute reported 06/30/2026 1187881580
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 05/16/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET Dispute reported 06/30/2026 1223266859
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 05/16/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET Dispute reported 06/30/2026 1223266861
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $800.00 05/16/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET Dispute reported 06/30/2026 1223266863
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,750.00 05/16/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET Dispute reported 06/30/2026 1223266865
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $574.00 05/16/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET Dispute reported 06/30/2026 1223266867
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,492.00 05/16/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET Dispute reported 06/30/2026 1223266869
Principal investigator 1 ABBVIE INC. $12,771.76 05/15/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202485015
Principal investigator 1 Boehringer Ingelheim International GmbH $12,606.00 05/14/2025 Non-covered Recipient Entity
Department Of Oral And Maxillofacial Surgery And Hospital Dentistry IU Health University Hospital
Proof of Clinical Principal in Crohn???s Disease No dispute reported 06/30/2026 1220631553
Principal investigator 1 ABBVIE INC. $33,309.12 05/07/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202482879
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $632.00 05/07/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL Dispute reported 06/30/2026 1223266857
Principal investigator 1 ABBVIE INC. $1,000.00 04/24/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202479040
Principal investigator 1 Eli Lilly and Company $775.77 04/23/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187882290
Principal investigator 1 ABBVIE INC. $25,593.00 04/17/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202477434
Principal investigator 1 ABBVIE INC. $1,043.60 04/03/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202470999
Principal investigator 1 ABBVIE INC. $500.00 03/20/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202465243
Principal investigator 1 ABBVIE INC. $28,407.60 03/20/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202465259
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $632.00 03/12/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL Dispute reported 06/30/2026 1223266845
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $632.00 03/12/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL Dispute reported 06/30/2026 1223266847
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $632.00 03/12/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL Dispute reported 06/30/2026 1223266849
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $632.00 03/12/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL Dispute reported 06/30/2026 1223266851
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.83 03/10/2025 Non-covered Recipient Entity
Department Of Oral And Maxillofacial Surgery And Hospital Dentistry IU Health University Hospital
Proof of Clinical Principal in Crohn's Disease No dispute reported 06/30/2026 1220994549
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.83 03/10/2025 Non-covered Recipient Entity
Department Of Oral And Maxillofacial Surgery And Hospital Dentistry IU Health University Hospital
Proof of Clinical Principal in Crohn's Disease No dispute reported 06/30/2026 1220994551
Principal investigator 1 ABBVIE INC. $10,222.96 03/07/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202461490
Principal investigator 1 ABBVIE INC. $12,771.00 02/06/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202447606
Principal investigator 1 ABBVIE INC. $500.00 02/06/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202447609
Principal investigator 1 Eli Lilly and Company $45,183.00 01/06/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187881488
Principal investigator 1 ABBVIE INC. $2,657.84 01/02/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202434218